NVCT
Nuvectis Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.94
+1.83%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$18.81
From 52W high−33.61%
Volume196876.00
Market cap$618.28M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$18.81
From 52W high
−33.61%
Volume
196876.00
Market cap
$618.28M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−20.6x
P/E (TTM)
—
RSI (14)
41.2
MomentumView details →
1D Return
+1.83%
YTD Return
+148.87%
SummaryUpdated Jun 1, 2026
Nuvectis Pharma, Inc. (NASDAQ:NVCT) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Fort Lee, New Jersey. The company went public in February 2022 and focuses on developing precision medicines to treat serious unmet medical needs in oncology. Nuvectis operates as a research and development-focused biotech firm with two primary drug candidates in its pipeline, targeting novel pathways in cancer treatment.
Similar companies
Latest newsMore news →
Nuvectis Pharma reported a net loss of $7.0 million for Q2 2026, compared to a net loss of $6.3 million in Q2 2025.77d agoNuvectis Pharma, Inc. announced an underwritten public offering of its common stock, with an option for underwriters to purchase additional shares.112d agoNuvectis entered into a license agreement with Haisco Pharmaceutical Group to acquire ex-China rights for two clinical-stage compounds, NXP100 and NXP200.120d ago